“On behalf of all the members of the board of directors and the permanent team, I welcome Catherine. Its expertise and knowledge of the Pharma/Healthtech sector will be valuable assets to implement the French Biotech roadmap in order to support growth and strengthen the competitiveness of French healthtech companies. I also want to warmly thank Olivier Chabanon for his commitment and his achievements under his direction. ” underlines Frédéric Girard, president of France Biotech.
“I am delighted to join France Biotech. Our particularly innovative and dynamic healthtech ecosystem has a key role to play in inventing the health of tomorrow. My priority will be to support entrepreneurs on their major issues: business financing, their development and their international visibility, market access, as well as development of the attractiveness of the sector to attract the best talents “continues Catherine Martre, Director General of France Biotech.
An experienced leader at the service of health innovation
A recognized professional in the health sector, Catherine Martre has more than 25 years of experience in management positions in biotechnology companies and large pharmaceutical groups. Its expertise and strategic and operational skills cover financing, management, scientific and clinical development, commercial development and market access.
Before joining France Biotech, Catherine Martre held several positions of responsibility in the pharmaceutical industry and biotechnologies. She was notably director of strategy and public affairs at Takeda France, then director of commercial operations and the Market Access at Advicenne. More recently, she exercised the functions of director general of Meletios Therapeutics, an innovative biotechnology company specializing in the development of treatments for viral infections.
A graduate of the Central School of Nantes and Centraleupelec, she began her career as a strategy consultant in the health and biotechnology sectors. She also has an independent administrator experience in biopharmaceutical companies.
Source : France Biotech